skip to Main Content
FDA Approves US Gammaplex 10%

FDA Approves US Gammaplex 10%

 FDA Approves Bio Products Laboratory's Gammaplex® 10% for Treatment of Primary immunodeficiency and Chronic Immune Thrombocytopenic Purpura Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies, today announced that the U.S. Food and Drug Administration (FDA) has…

Read more
Back To Top